希少疾患に変化をもたらす：KOLの特定と関与の最適化

本レポートでは、希少疾患治療薬開発におけるKOL (Key Opinion Leader) の重要な役割について掘り下げています。本レポートは、製薬企業の専門家に対し、臨床的な見識を提供し規制状況をナビゲートするために不可欠なKOLを特定し、KOLと関わるための戦略について包括的な分析を提供しています。このような専門家を見つけ、協力するための課題を克服し、ツールやアプローチを活用してエンゲージメントを強化し、KOLが治療経路にもたらす価値を最適化するための洞察を得ることができます。また、KOLとの関係を構築・維持し、彼らの専門知識を医薬品開発プロセスに効果的に組み込むためのベストプラクティスについても解説しています。

回答された主な質問：

• 1.なぜ希少疾患KOLは医薬品開発において重要なのか？
• 2.希少疾患KOLの特定にはどのような課題があるか？
• 3.KOLを特定する上での課題はどのように克服できるか？
• 4.どのようなツールやアプローチが希少疾患KOLの発掘に有効か？
• 5.希少疾患KOLとの共同研究において、どのような戦術が成功するか？
• 6.MA (メディカルアフェアーズ) は希少疾患KOLがもたらす価値をどのように最適化できるか？

主要企業

当社のレポートの特徴は？

FirstWord Reportsは、製薬部門に特化した信頼できる業界リーダーとして、バイオ医薬の専門家や意思決定者のために詳細で実用的な洞察をお届けします。当社の深い業界知識により、お客様が新たな動向を把握し、複雑な課題を効果的に解決するのに役立つ、適切で価値ある洞察を提供することができます。広範な調査と一流の専門家やKOLによる独立した公平な洞察に裏打ちされた当社のレポートは、お客様が必要とする正確性と信頼性を提供します。他では入手できないインタビューやデータへの独占アクセス、継続的な市場モニタリングにより、市場力学を包括的に把握することができます。40を超えるダイナミックな疾患領域をカバーし、KOLの洞察や定量的な医師調査を含む医師インテリジェンス、さらにMA (メディカルアフェアーズ)、デジタルヘルス、セールス＆マーケティング、市場アクセス、その他の領域における問題についての業界専門家の見解を提供する当社のレポートは、よりスマートでデータ駆動型の意思決定を行い、変化の激しい業界で競争力を維持するための力となります。

This report delves into the pivotal role of Key Opinion Leaders (KOLs) in the realm of rare disease drug development. It provides pharmaceutical professionals with a comprehensive analysis of the strategies for identifying and engaging with KOLs, who are essential for offering clinical insights and navigating regulatory landscapes. Gain insights into overcoming the challenges of finding and collaborating with these experts, leveraging tools and approaches to enhance engagement, and optimising the value KOLs bring to treatment pathways. The report also explores best practices for building and maintaining relationships with KOLs, ensuring that their expertise is effectively integrated into the drug development process.

Key Questions Answered:

• 1. Why are rare disease KOLs crucial in drug development?
• 2. What challenges exist in identifying rare disease KOLs?
• 3. How can these challenges in identifying KOLs be overcome?
• 4. What tools and approaches are effective for finding rare disease KOLs?
• 5. What tactics are successful in collaborating with rare disease KOLs?
• 6. How can medical affairs optimise the value brought by rare disease KOLs?

Key Companies:

Partial List of Participating Experts:

• Former Medical Consultant at BridgeBio Pharma, based in Italy
• Former UK country medical director at pharmaceutical companies with rare disease treatments, based in the UK
• European Medical Head at a pharmaceutical company in the top 50 by global sales in 2023, based in the UK
• Former Lead, Global Early-Stage Medical Affairs, Mitochondrial and Rare Disease at Astellas Pharma, based in the UK
• A Senior Manager, Medical Affairs, working at a global biopharmaceutical company based in the US
• A Senior Medical Director at a commercial-stage biopharmaceutical company based in the US
• A Director, Medical Affairs, working in the rare disease area at a biopharmaceutical company based in the US
• A Senior Global Medical Director at a pharmaceutical company in the top 10 by global sales in 2023, based in the US

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.